THERAPY DOSSIER · th-2fae406a7ee8

Prostacyclin (PGI2, epoprostenol)

Drug · AGONIST at the prostanoid IP receptor (mec_id 666, target CHEMBL1995); direct_interaction and disease_efficacy true. ATC B01AC09; natural_product TRUE; parenteral only.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: AGONIST at the prostanoid IP receptor (mec_id 666, target CHEMBL1995); direct_interaction and disease_efficacy true. ATC B01AC09; natural_product TRUE; parenteral only.
Target: CHEMBL1995
Injury models: Crush
Reported indication: Pulmonary arterial hypertension (chronic); also used as renal-replacement-circuit anticoagulant in some regions (Flolan/Veletri)
First approval: 1995
Development stage: Approved for PAH; acute reperfusion/AKI use investigational
ChEMBL record: CHEMBL1139 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Prostacyclin; PGI2; PGX; Prostaglandin I2; Flolan; Veletri; U-53217; epoprostenol sodium CHEMBL962
Note: Not recorded

Clinical trials 3

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02251041 ↗Injury indicationPHASE2completed

Combined Drug Approach (incl. Epoprostenol) to Prevent Ischemia-reperfusion Injury During Liver Transplantation (CAPITL)

Reperfusion Injury

Enrolment: 143 · Results not recorded

NCT00890214 ↗PHASE4completed

Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure

Acute Kidney Failure

Enrolment: 23 · Results not recorded

NCT04594629 ↗PHASE1unknown

Efficacy of Nebulized PGI2 Versus Nebulized Nitroglycerine for Pulmonary Hypertension After Valve Replacement

Pulmonary Hypertension

Enrolment: 120 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23032812 ↗2012Reported benefit

Prostacyclin reduces plasma volume loss after skeletal muscle trauma in the rat.

RatCrushLimb / muscle crushSprague-DawleyMaleInfusion2 ng/kg per minuteStarted after the trauma

Model: Controlled standardised blunt trauma to the abdominal rectus muscle in anaesthetised animals

Prostacyclin limited the fall in plasma volume 3 h after blunt muscle trauma to 11 per cent compared with 22 per cent in saline treated animals and lowered interleukin 6, while the transcapillary escape rate for albumin did not differ significantly.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…